EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Chronic Myeloid Leukemia: who should get a treatment-free trial and how?

Sarit Assouline

Canadian Hematology Today · 2022

DOI: 10.58931/cht.2022.1320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Sarit Assouline. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment with a BCR::ABL1 targeted tyrosine kinase inhibitor (TKI) has afforded a near-normal life expectancy for most patients with chronic myelogenous leukemia (CML). Approximately half of CML patients achieve a deep molecular response with TKI therapy and can discontinue treatment. In these patients, the CML can remain in prolonged remission, and patients can experience an improvement in quality of life. The European Leukemia Network (ELN) and the National Comprehensive Cancer Network (NCCN) provide the most up-to-date frameworks for treatment-free trials (TFTs), reflecting best practices from over 13 clinical trials published since the concept first entered the CML vernacular around 2010. Provincial guidelines also exist, such as those published in Quebec by the Groupe Québécois de Recherche en LMC-NMP (the Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Quebec Research Group). The discontinuation of therapy for patients with CML in deep remission marks a potential shift from the management of CML as a chronic illness to the potential for a curative approach to CML. However, for now, only 50% of eligible patients have undergone successful TFT; optimal patient selection and monitoring is required to ensure the best outcomes with such a management strategy.

Zitieren

APA

Assouline, S. (2022). Chronic Myeloid Leukemia: who should get a treatment-free trial and how?. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1320

Vancouver

Assouline S. Chronic Myeloid Leukemia: who should get a treatment-free trial and how?. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1320

BibTeX
@article{Assouline2022,
  author = {Assouline, Sarit},
  title = {Chronic Myeloid Leukemia: who should get a treatment-free trial and how?},
  journal = {Canadian Hematology Today},
  year = {2022},
  doi = {10.58931/cht.2022.1320}
}
Kostenlos starten →